Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using topical minoxidil did not affect the percentage of hair survival after transplantation for androgenetic alopecia, but did reduce initial postoperative hair shedding in 60% of grafts.

This study observed that while both minoxidil and botanically-derived 5-alpha reductase inhibitors significantly increased hair count and diameter in women with female pattern hair loss, minoxidil was more effective, especially for greater hair diameter increases, but had more troublesome side effects.

In this survey, dermatologists in India reported preferring alcohol-free minoxidil combined with procapil and finasteride over traditional alcohol-based formulations for managing androgenetic alopecia, citing better tolerance and patient adherence.

This meta-analysis found that while PRP therapy may result in higher patient satisfaction and better negative hair pull test results, it shows no clear advantage over minoxidil in terms of hair density or regrowth in androgenetic alopecia treatment.

This study concluded that platelet-rich plasma is nearly as effective as topical minoxidil for treating androgenetic alopecia, with PRP improving hair density and minoxidil boosting terminal hair count.

In this study of female pattern hair loss, oral finasteride 5 mg and topical minoxidil 5% both significantly improved hair density and patient satisfaction over 6 months, outperforming finasteride 2 mg, which showed limited improvement beyond the third month. All treatments were deemed safe.

This study reviewed randomized controlled trials to assess whether adding platelet-rich plasma injections to a Minoxidil regimen offers any benefit in treating androgenetic alopecia, but results are not reported in the abstract.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

In this study, 70% of female androgenetic alopecia patients who did not respond to standard minoxidil experienced clinical improvement after switching to a propylene glycol-free, witch hazel-based 5% minoxidil sulfate solution, with the treatment also being well-tolerated.

In this case report, a young male developed acute central serous chorioretinopathy after using 5% topical minoxidil for androgenic alopecia, which resolved after discontinuation of the drug and focal laser treatment.

This study reports a new optimized protocol for isolating and labeling single cells from neonatal mouse skin, enabling high-quality single cell RNA sequencing for lineage-specific cell analysis.

The document gives treatment advice for various skin conditions, like using metronidazole for perioral dermatitis and minoxidil for hair loss.

This study found a high discontinuation rate of topical minoxidil among patients with androgenetic alopecia, largely influenced by short treatment duration, lack of efficacy, and adverse effects.

The authors provide an overview of using topical minoxidil to manage female pattern hair loss in Indian clinical practice, emphasizing its significance as the main treatment method.

In this study, researchers examined a new propylene glycol-free 5% minoxidil lotion for 6 months among individuals with androgenic alopecia and found it demonstrated good clinical efficacy, with 74% showing a positive response, and very high cosmetic acceptability and tolerability, comparable to traditional formulations.

This study found that the patient receiving microneedling and platelet-rich plasma treatment showed earlier significant improvements and high satisfaction compared to the patient treated with microneedling and topical minoxidil.

In this study, microneedling combined with platelet-rich plasma led to earlier improvements and high patient satisfaction in a man with androgenic alopecia, compared to microneedling with topical minoxidil.

This review discusses the necessity for hair transplant surgeons to be well-versed in both surgical and medical treatments for various forms of alopecia, and it reports no new results.

This review discusses the evaluation and management of male baldness and related conditions, but reports no new clinical results.

This review discusses recent advances in the diagnosis and management of female pattern hair loss but reports no new clinical results.

This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.

This review discusses the characteristics and management options for female pattern hair loss, highlighting the unclear role of androgens and the psychosocial impact, and reports no new clinical results.

This case report describes the use of topical minoxidil to successfully promote facial hair growth in a 17-year-old trans male unable to start testosterone therapy, with skin dryness as the only reported side effect.

This review covers androgenetic alopecia's epidemiology, pathogenesis, current management options, and research trends, concluding that no definitive cure exists despite extensive interest and ongoing genetic research efforts.

In this randomized controlled trial, oral minoxidil at 2.5 mg daily was more effective than topical minoxidil for increasing hair thickness, counts, and density in men with androgenetic alopecia, demonstrating more significant improvements and better compliance over six months.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

In this study, a review of existing trials reported that combining minoxidil with platelet-rich plasma therapy significantly improved outcomes for androgenetic alopecia more than minoxidil alone, and offered generally superior results compared to platelet-rich plasma monotherapy, while maintaining a safe profile similar to individual treatments.

This study observed that 5% minoxidil milky lotion increased hair density more than the standard solution at 8 weeks in males with androgenetic alopecia, but their efficacy was similar at later visits.

In this study, topical minoxidil 7% with dutasteride 0.5 mg showed higher efficacy but more adverse effects compared to minoxidil 7% with finasteride 1 mg for treating androgenetic alopecia.